SEVITERONEL - AN OVERVIEW

-mutated tumors. However, only a portion of those patients responds to immune checkpoint or PARP inhibitors and in some cases those who do react normally create resistance and relapse.Mechanistically, we report differential binding of AR to focus on genes within the presence of enzalutamide and seviteronel, suggesting different mechanisms of action